- Home
- IMMX vs RLMD Comparison
IMMX vs RLMD Comparison
Compare IMMX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RLMD
- Stock Information
- Founded
- IMMX 2014
- RLMD 2004
- Country
- IMMX United States
- RLMD United States
- Employees
- IMMX N/A
- RLMD N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- RLMD Health Care
- Exchange
- IMMX Nasdaq
- RLMD Nasdaq
- Market Cap
- IMMX 65.5M
- RLMD 53.4M
- IPO Year
- IMMX 2021
- RLMD N/A
- Fundamental
- Price
- IMMX $2.10
- RLMD $1.59
- Analyst Decision
- IMMX Strong Buy
- RLMD Buy
- Analyst Count
- IMMX 1
- RLMD 3
- Target Price
- IMMX $8.00
- RLMD $5.00
- AVG Volume (30 Days)
- IMMX 181.7K
- RLMD 1.6M
- Earning Date
- IMMX 11-11-2025
- RLMD 11-06-2025
- Dividend Yield
- IMMX N/A
- RLMD N/A
- EPS Growth
- IMMX N/A
- RLMD N/A
- EPS
- IMMX N/A
- RLMD N/A
- Revenue
- IMMX N/A
- RLMD N/A
- Revenue This Year
- IMMX N/A
- RLMD N/A
- Revenue Next Year
- IMMX N/A
- RLMD N/A
- P/E Ratio
- IMMX N/A
- RLMD N/A
- Revenue Growth
- IMMX N/A
- RLMD N/A
- 52 Week Low
- IMMX $1.26
- RLMD $0.24
- 52 Week High
- IMMX $3.20
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- IMMX 42.26
- RLMD 74.57
- Support Level
- IMMX $2.09
- RLMD $1.44
- Resistance Level
- IMMX $2.34
- RLMD $1.72
- Average True Range (ATR)
- IMMX 0.16
- RLMD 0.24
- MACD
- IMMX 0.01
- RLMD 0.05
- Stochastic Oscillator
- IMMX 35.90
- RLMD 86.90
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.